Evidence map›Paper›PMID 36881161›Full record

ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2023

Nursing care and management of adverse events for patients with BRAF

Matthew Fowler, Helene Tobback, Alice Karuri, Paz Fernández-Ortega

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Expert consensus on the optimal management of BRAFAsia-Pacific journal of clinical oncology · 2025
    Article
  4. BRAFAdvances in therapy · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 3 countries.

Matthew FowlerUniversity Hospitals of Derby and Burton NHSFT, Uttoxeter Road, DE22 3NE, Derby, UK. matthew.fowler@nhs.net.
Helene TobbackUZ Leuven, Gasthuisberg Campus, Leuven, Belgium.
Alice KaruriBarts and the London NHS Trust, London, UK.
Paz Fernández-OrtegaInstitut Català d'Oncologia, Granvia de l'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain.
Barts Health NHS Trust · GBInstitut Català d'Oncologia · ESUniversitair Ziekenhuis Leuven · BEUniversity Hospitals of Derby and Burton NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Encorafenib is a B-Raf proto-oncogene serine/threonine-protein kinase (BRAF) inhibitor, approved in the EU and USA, in combination with the epidermal growth factor receptor (EGFR) inhibitor cetuximab, for the treatment of patients with BRAF

Indexed as

Colonic NeoplasmsNursing CareRectal NeoplasmsCarbamatesCetuximabErbB ReceptorsHumansProto-Oncogene Proteins B-rafSulfonamidesBRAF protein, humanCarbamatesCetuximabencorafenibErbB ReceptorsProto-Oncogene Proteins B-rafSulfonamidesBRAF MutationCetuximabColorectal cancerEncorafenibNursing roleToxicity

Identifiers

PMID36881161
PMCPMC9989561
OpenAlexW4323347520

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.